Targeting NFκB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2

Cancer Biology and Therapy

Volumn 11, Issue 7, 2011, Pages 678-689

  Antoon, James W ^a   White, Martin D ^a   Slaughter, Evelyn M ^a   Driver, Jennifer L ^a   Khalili, Hafez S ^a   Elliott, Steven ^a   Smith, Charles D ^b   Burow, Matthew E ^a   Beckman, Barbara S ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Breast cancer; Ceramide; Chemoresistance; NFkappaB; Sphingolipids; Sphingosine kinase; Sphingosine 1 phosphate; TNF

Indexed keywords

ABC 294640; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PHOSPHOTRANSFERASE INHIBITOR; SPHINGOSINE KINASE 2; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; 3 (4 CHLOROPHENYL) ADAMANTANE 1 CARBOXYLIC ACID (PYRIDIN 4 YLMETHYL)AMIDE; 3-(4-CHLOROPHENYL)-ADAMANTANE-1-CARBOXYLIC ACID (PYRIDIN-4-YLMETHYL)AMIDE; ADAMANTANE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; ESTROGEN RECEPTOR; NF KAPPA B KINASE; NF-KAPPA B KINASE; PHOSPHOTRANSFERASE; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; SPHINGOSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; FEMALE; HUMAN; IC 50; IMMUNOFLUORESCENCE; IN VITRO STUDY; MOUSE; NONHUMAN; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; VALIDATION PROCESS; XENOGRAFT; ANIMAL; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE;

ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953314461     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.7.14903     Document Type: Article

References (45)

1. Meacham WD, Antoon JW, Burow ME, Struckhoff AP, Beckman BS. Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Exp Biol Med (Maywood) 2009; 234:1253-63; PMID:19546354.
2. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008; 49:413-40; PMID:18751921.
3. Sukocheva O, Wang L, Verrier E, Vadas MA, Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology 2009; 150:4484-92; PMID:19706837.
4. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1- phosphate. Nature 1996; 381:800-3; PMID:8657285.
5. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63:5962-9; PMID:14522923.
6. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008; 112:41-52; PMID:18058224.
7. Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res 2002; 281:115-27; PMID:12441135.
8. Dai Y, Lawrence TS, Xu L. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor kappaB. Am J Transl Res 2009; 1:1-15; PMID:19966933.
9. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100:2952-60; PMID:9399940.
10. Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau AW, et al. Activation of NFkappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 2000; 21:871-9; PMID:10783306.
11. Nakshatri H, Goulet RJ Jr. NFkappaB and breast cancer. Curr Probl Cancer 2002; 26:282-309; PMID:12429950.
12. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NFkappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17:3629-39; PMID:9199297.
13. Hernandez-Vargas H, Rodriguez-Pinilla SM, Julian-Tendero M, Sanchez-Rovira P, Cuevas C, Anton A, et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NFkappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 2007; 102:157-72; PMID:17039268.
14. Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 1998; 95:14196-201; PMID:9826677.
15. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, et al. Role for sphingosine kinase 1 in colon carcinogenesis. Faseb J 2008; 23:405-14; PMID:18824518.
16. Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA, et al. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. Faseb J 2008; 23:143-52; PMID:18815359.
17. Chumanevich AA, Poudyal D, Cui X, Davis T, Wood PA, Smith CD, et al. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 2010; 31:1787-93; PMID:20688834.
18. Billich A, Bornancin F, Mechtcheriakova D, Natt F, Huesken D, Baumruker T. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1beta and TNFalpha induced production of inflammatory mediators. Cell Signal 2005; 17:1203-17; PMID:16038795.
19. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006; 1758:2016-26; PMID:16996023.
20. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 2005; 280:37118-29; PMID:16118219.
21. Sankala HM, Hait NC, Paugh SW, Shida D, Lepine S, Elmore LW, et al. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 2007; 67:10466-74; PMID:17974990.
22. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010; 333:129-39; PMID:20061445.
23. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010; 333:454-64; PMID:20179157.
24. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010; 333:129-39; PMID:20061445.
25. Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010; 151:5124-35; PMID:20861237.
26. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 2003; 278:46832-9; PMID:12954646.
27. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990; 50:6075-86; PMID:1975513.
28. Brown JM, Wouters BG. Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59:1391-9; PMID:10197600.
29. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010; 333:454-64; PMID:20179157.
30. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 2004; 309:523-32; PMID:14742741.
31. Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, et al. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 2004; 24:1473-80; PMID:15138590.
32. Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-Burow BM, Beckman BS, et al. PI3-K/AKT regulation of NFkappaB signaling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun 2000; 271:342-5; PMID:10799299.
33. Wu JT, Kral JG. The NFkappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005; 123:158-69; PMID:15652965.
34. Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN, et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 2008; 53:997-1012; PMID:18058233.
35. Schnitzer SE, Weigert A, Zhou J, Brune B. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol Cancer Res 2009; 7:393-401; PMID:19240180.
36. Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS. NFkappaB-mediated chemoresistance in breast cancer cells. Surgery 2001; 130:143-50; PMID:11490342.
37. Ahmed KM, Cao N, Li JJ. HER-2 and NFkappaB as the targets for therapy-resistant breast cancer. Anticancer Res 2006; 26:4235-43; PMID:17201139.
38. Duran A, Diaz-Meco MT, Moscat J. Essential role of RelA Ser311 phosphorylation by zetaPKC in NFkappaB transcriptional activation. EMBO J 2003; 22:3910-8; PMID:12881425.
39. Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Foroozesh M. Design, synthesis and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem 2009; 52:5748-52; PMID:19694470.
40. Antoon JW, Liu J, Ponnapakkam AP, Gestaut MM, Foroozesh M, Beckman BS. Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemother Pharmacol 2010; 65:1191-5; PMID:20155475.
41. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, et al. Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 1998; 58:4940-6; PMID:9810003.
42. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, et al. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 2009; 121:293-300; PMID:19597705.
43. Boue SM, Tilghman SL, Elliott S, Zimmerman MC, Williams KY, Payton-Stewart F, et al. Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology 2009; 150:2446-53; PMID:19116342.
44. Bratton MR, Frigo DE, Vigh-Conrad KA, Fan D, Wadsworth S, McLachlan JA, et al. Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis 2009; 30:106-13; PMID:18791200.
45. Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, et al. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res 2006; 12:7159-64; PMID:17145841.